Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Exclusive Story Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorAuthor: Jeffrey Neal Johnson. Date Posted: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces renewed volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of roughly $245 per share, creating a divergence that has caught Wall Street's attention. This rally defies the common perception of the healthcare giant as a slow-moving, boring stock. Over the last 30 days, shares have climbed about 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, dependable cash flow, and operational execution. For investors watching the ticker today, Feb. 24, 2026, note a specific calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will likely adjust downward by the amount of the upcoming dividend, $1.30 per share. That is a mechanical market adjustment, not a reflection of the company's underlying performance. For income-focused investors, this technical dip often represents an attractive entry point rather than a signal to sell. 64 Years of Unbroken Growth The primary argument for holding Johnson & Johnson during turbulent market cycles revolves around its immense financial stability and its role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings — firms that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has raised its dividend for 64 consecutive years, a track record that spans multiple recessions, market crashes, and geopolitical conflicts. This reliability is a rare commodity in a market still fixated on speculative growth. Currently, the stock yields about 2.12%, based on an annual payout of $5.20 per share. While higher yields exist in the bond market or riskier sectors, J&J's appeal is the combination of growth and safety. The dividend is supported by a large liquidity cushion: management projects free cash flow of roughly $21 billion in 2026. That cash generation helps ensure the company can continue to pay shareholders, invest in R&D, and address legal expenses without heavy borrowing. For risk-averse investors, another compelling metric is the stock's beta. Beta measures how much a stock moves compared with the overall market (S&P 500). A beta of 1.0 means the stock moves in lockstep with the market; Johnson & Johnson currently has a beta of just 0.35. Historically, the stock has been about 65% less volatile than the broader market. When tech stocks swing wildly, J&J tends to hold its ground. Adding JNJ to a portfolio heavy in technology acts as a mathematical shock absorber, dampening overall volatility while preserving equity exposure. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about safe stocks is that they cannot grow. Johnson & Johnson is disproving that with a strategic pivot that is producing results. Management has issued guidance for 2026 projecting full-year revenue to exceed $100 billion for the first time in company history, along with adjusted earnings per share of about $11.53. This growth is driven by a reinvention of its pharmaceutical division, now branded Innovative Medicine. For years investors worried about the patent cliff for Stelara, a blockbuster immunology drug that lost exclusivity in 2025. Typically, a top drug losing exclusivity leads to steep revenue declines. J&J has absorbed that gap through the strong performance of new blockbuster drugs. Two key assets are driving this resilience: - Darzalex: This oncology powerhouse generates roughly $14 billion in annual sales and has solidified the company's leadership in multiple myeloma treatment worldwide.
- Tremfya: Positioned as a successor to Stelara, Tremfya recently released strong three-year data showing improved remission rates for ulcerative colitis. Those clinical results are important for retaining market share in the competitive immunology space.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into the MedTech division, which has shifted toward high-growth, high-margin technologies. A notable example is the integration of Shockwave Medical, acquired to modernize the cardiovascular portfolio. Shockwave uses intravascular lithotripsy (IVL) technology, which applies sonic pressure waves to break up calcified plaque in arteries—an approach similar to how kidney stones are treated. IVL represents a meaningful upgrade over traditional angioplasty balloons. Owning this technology gives Johnson & Johnson a high-growth asset that complements its broader cardiovascular and surgical businesses. The company is also advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals intent to compete in the rapidly expanding soft-tissue robotics market. These high-tech devices typically carry higher profit margins and create sticky relationships with hospital systems, providing a long-term earnings tailwind that extends beyond basic consumables or surgical tools. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is actively reshaping the corporate structure. A major development is the potential separation or sale of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports suggest the company is exploring a large-scale divestiture. Divesting the orthopedics unit is a classic addition-by-subtraction move. Orthopedics is a mature, lower-growth business compared with the booming fields of oncology and cardiovascular devices. Shedding this slower unit would likely improve overall revenue growth rates and profit margins. A sale would also generate a significant lump-sum payment—potentially billions—providing capital for acquisitions, R&D, or share buybacks. Legal risks remain part of the balanced case on Johnson & Johnson. The company continues to face litigation over talc products, including a recent $1.5 billion verdict that kept the issue in the headlines. A new commercial lawsuit from Bayer over marketing claims for prostate cancer drugs has added further noise. Still, the stock's recent rally suggests investors are looking past these headlines. The prevailing bullish view is that Johnson & Johnson has the financial depth to manage these liabilities without disrupting operations. With more than $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and roughly $21 billion in expected free cash flow, the company has a financial fortress capable of absorbing settlements. That makes these legal battles a balance-sheet item rather than an existential threat to the dividend or the business. Capital Preservation With Upside Johnson & Johnson has evolved from a slow-moving conglomerate into a more focused, high-tech healthcare company. By shedding its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting its orthopedics unit, the company is streamlining to concentrate on high-growth opportunities in pharmaceuticals and medical technology. Although the stock is no longer a bargain—trading near all-time highs—it provides a compelling mix of capital preservation and upside. The combination of a 64-year dividend growth streak, a low volatility profile, and a clear path to more than $100 billion in revenue makes Johnson & Johnson an attractive option for 2026. For investors tired of the technology sector's unpredictability, J&J demonstrates that, in the current market, boring can be both beautiful and profitable.
| 
